Home › Funds › Aisling Capital Management LP › EPRX

Aisling Capital Management LP position in EPRX

Eupraxia Pharmaceuticals Inc · Health Care

Aisling Capital Management LP reported holding 325,000 shares of EPRX (Eupraxia Pharmaceuticals Inc) in its Q3 2026 13F filing — a position valued at US$3.0M, representing 0.99% of its reported portfolio and ranking #8 among its reported holdings. Aisling Capital Management LP has disclosed EPRX holdings in 3 of the last 3 reported quarters, going back to Q1 2026.

Latest position (Q3 2026)325.00K sh
Reported value held$2.96M
Portfolio Weight0.99%
First reportedQ1 2026
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Aisling Capital Management LP's EPRX position evolved

Aisling Capital Management LP first disclosed a stake in EPRX in Q1 2026 at 325,000 shares (US$2.4M). The position peaked in Q3 2026 at 325,000 shares, worth US$3.0M. Across 3 filings, Aisling Capital Management LP held the position steady without any share-count change. The most recent filing (Q3 2026) shows 325,000 shares valued at US$3.0M.

Quarter by quarter

QuarterSharesValueChange
Q1 2026 325.00K $2.35M New
Q2 2026 325.00K $2.15M Hold
Q3 2026 325.00K $2.96M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About EPRX and 13F data

EPRX (Eupraxia Pharmaceuticals Inc) is a Health Care company. 70 other funds we track also report a position in EPRX — the largest reported positions include Vivo Capital, LLC (US$12.3M), PFM Health Sciences, LP (US$8.0M), GREAT POINT PARTNERS LLC (US$7.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding EPRX

All EPRX fund holders →

FAQ

How long has Aisling Capital Management LP held EPRX?

Aisling Capital Management LP has disclosed EPRX holdings in 3 of the last 3 reported quarters, going back to Q1 2026.

What is Aisling Capital Management LP's current position in EPRX?

As of Q3 2026, Aisling Capital Management LP holds 325.00K shares of EPRX (Eupraxia Pharmaceuticals Inc), valued at $2.96M, representing 0.99% of its reported portfolio and ranking #8.

Has Aisling Capital Management LP been buying or selling EPRX?

In the latest 13F filing (Q3 2026), Aisling Capital Management LP held unchanged its position in EPRX. The position peaked in Q3 2026 at 325.00K shares.

Which other funds hold EPRX?

Other major institutional holders of EPRX include Vivo Capital, LLC, PFM Health Sciences, LP, GREAT POINT PARTNERS LLC, among 70 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.